Bristol Myers’ HCC Combo Drug Accepted for FDA Review – Bristol-Myers Squibb (NYSE:BMY)
Bristol Myers BMY introduced that the FDA has accepted its supplemental Biologics License Software (sBLA) for the immunotherapy drug, Opdivo ...
Tag: HCC
Bristol Myers BMY introduced that the FDA has accepted its supplemental Biologics License Software (sBLA) for the immunotherapy drug, Opdivo ...